DECAPRYN
LOE ApproachingNDAORALTABLET
Approved
Apr 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECAPRYN is an oral tablet small molecule approved in 1948 by Sanofi with an unknown mechanism of action and indication profile. The drug's exact therapeutic use and pharmacologic class are not documented in current data sources, suggesting it may be a legacy product with limited contemporary clinical visibility.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team is likely in defensive/transition mode with minimal growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DECAPRYN currently has zero linked job openings, indicating minimal active hiring and career momentum. Working on this product offers limited growth potential given its mature, LOE-approaching status with no clinical pipeline.
Brand ManagerField Sales Representative
Worked on DECAPRYN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.